| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3983306 | Clinical Radiology | 2009 | 13 Pages |
Abstract
Positron-emission tomography–computed tomography (PET/CT) is rapidly being integrated into the imaging pathways of several different tumour types, most frequently using the glucose analogue 2- [18F]-fluoro-2-deoxy-d-glucose (FDG). Integrated FDG-PET/CT combines functional and anatomical imaging to improve sensitivity and specificity of tumour detection. The aim of this article is to review the established, emerging, and future roles of FDG-PET/CT in the management of patients with colorectal cancer (CRC).
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
R.A. Herbertson, A.F. Scarsbrook, S.T. Lee, N. Tebbutt, A.M. Scott,